P. Kefalas

发表

Cell-based therapy technology classifications and translational challenges

J. Hyllner, N. Mount, S. Ward, 2015, Philosophical Transactions of the Royal Society B: Biological Sciences.

Clinical Adoption of Advanced Therapies: Challenges and Opportunities.

M. Sharpe, P. Kefalas, J. Barry, 2020, Journal of pharmaceutical sciences.

Market access pathways for cell therapies in France

M. Toumi, P. Kefalas, C. Rémuzat, 2015, Journal of market access & health policy.

Reimbursement of licensed cell and gene therapies across the major European healthcare markets

P. Kefalas, Jesper Jørgensen, 2015, Journal of market access & health policy.

CRP2 transcript expression pattern in embryonic chick limb

M. Bonnin, P. Kefalas, D. Duprez, 2002, Mechanisms of Development.

Concise Review: The High Cost of High Tech Medicine: Planning Ahead for Market Access

P. Kefalas, R. Maziarz, Stephanie Farnia, 2017, Stem cells translational medicine.

Oxidative stability and minor constituents of virgin olive oil and cold-pressed rapeseed oil

K. Wähälä, M. Heinonen, A. Hopia, 2002 .

Healthcare costs and outcomes of managing β‐thalassemia major over 50 years in the United Kingdom

J. Guest, P. Kefalas, D. Weidlich, 2016, Transfusion.

Data collection infrastructure for patient outcomes in the UK – opportunities and challenges for cell and gene therapies launching

Laura Mungapen, P. Kefalas, L. Mungapen, 2019, Journal of market access & health policy.

Systematic literature review of treatments for management of complications of ischemic central retinal vein occlusion

S. E. Bradshaw, P. Kefalas, M. Mwamburi, 2016, BMC Ophthalmology.

Bringing regenerative medicines to the clinic: the future for regulation and reimbursement.

Christopher McCabe, Claire Packer, Tania Bubela, 2015, Regenerative medicine.

Upgrading the SACT dataset and EBMT registry to enable outcomes-based reimbursement in oncology in England: a gap analysis and top-level cost estimate

P. Kefalas, Jesper Jørgensen, 2019, Journal of market access & health policy.

The use of innovative payment mechanisms for gene therapies in Europe and the USA.

P. Kefalas, Jesper Jørgensen, 2021, Regenerative medicine.

Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries

P. Kefalas, E. Hanna, Jesper Jørgensen, 2020, Journal of market access & health policy.

The potential price and access implications of the cost-utility and budget impact methodologies applied by NICE in England and ICER in the US for a novel gene therapy in Parkinson’s disease

P. Kefalas, Jesper Jørgensen, Spiros Servos, 2018, Journal of market access & health policy.

Using analogue data to substantiate long-term durability of gene therapies: a narrative review.

P. Kefalas, M. Sharpe, Laura Beswick, 2022, Regenerative medicine.

Annuity payments can increase patient access to innovative cell and gene therapies under England’s net budget impact test

P. Kefalas, Jesper Jørgensen, 2017, Journal of market access & health policy.

Establishing the cost of implementing a performance-based, managed entry agreement for a hypothetical CAR T-cell therapy

P. Kefalas, L. Mungapen, Matthew B Durdy, 2018, Journal of market access & health policy.